|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion显示文摘The recent outbreak of coronavirus disease(COVID-19)caused by SARS-CoV-2 infection in Wuhan,China has posed a serious threat to global public health.To develop specific anti-coronavirus therapeutics and prophylactics,the molecular mechanism that underlies viral infection must first be defined.Therefore,we herein established a SARS-CoV-2 spike(S)protein-mediated cell-cell fusion assay and found that SARS-CoV-2 showed a superior plasma membrane fusion capacity compared to that of SARS-CoV.We solved the X-ray crystal structure of six-helical bundle(6-HB)core of the HR1 and HR2 domains in the SARS-CoV-2 S protein S2 subunit revealing that several mutated amino acid residues in the HR1 domain may be associated with enhanced interactions with the HR2 domain.We previously developed a pan-coronavirus fusion inhibitor,EK1,which targeted the HR!domain and could inhibit infection by divergent human coronaviruses tested,including SARS-CoV and MERS-CoV.Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM,about 241-and 149-fold more potent than the original EK1 peptide,respectively.EK1C4 was also highly effective against membrane fusion and infection of other human coronavirus pseudoviruses tested,including SARS-CoV and MERS-CoV,as well as SARSr-CoVs,and potently inhibited the replication of 5 live human coronaviruses examined,including SARS-CoV-2.Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from infection,suggesting that EK1C4 could be used for prevention and treatment of infection by the currently circulating SARS-CoV-2 and other emerging SARSr-CoVs. | Shuai Xia Meiqin Liu Chao Wang Wei Xu Qiaoshuai Lan Siliang Feng Feifei Qi Linlin Bao Lanying Du Shuwen Liu Chuan Qin Fei Sun Zhengli Shi Yun Zhu Shibo Jiang Lu Lu | 2020 | Cell Research2020，30，4： | 81 |
| 2 | Characterization of the receptor-binding domain(RBD)of 2019 novel coronavirus:implication for development of RBD protein as a viral attachment inhibitor and vaccine显示文摘The outbreak of Coronavirus Disease 2019(COVID-19)has posed a serious threat to global public health,calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),also known as 2019 novel coronavirus(2019-nCoV).The CoV spike(S)protein plays the most important roles in viral attachment,fusion and entry,and serves as a target for development of antibodies,entry inhibitors and vaccines.Here,we identified the receptor-binding domain(RBD)in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2(ACE2)receptors.SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and,hence,attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells,thus inhibiting their infection to host cells.SARS-CoV RBD-specific antibodies could crossreact with SARS-CoV-2 RBD protein,and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2,suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection. | Wanbo Tai Lei He Xiujuan Zhang Jing Pu Denis Voronin Shibo Jiang Yusen Zhou Lanying Du | 2020 | Cellular & Molecular Immunology2020，17，6： | 35 |
| 3 | The Hardy Rubber Tree Genome Provides Insights into the Evolution of Polyisoprene Biosynthesis显示文摘Eucommia ulmoides,也叫的强壮的橡胶树,是一棵经济地重要的树;然而,它的染色体顺序的缺乏 ?限制基本生物研究和这植物种的应用研究。这里,我们在场它的 1.2-Gb 染色体的一个高质量的集会(支架 N50 ?=? 1.88 Mb ) 与至少 26 ? 为 E 的 723 预言的基因。ulmoides,顺序 Garryales 的首先定序的染色体,它用联合定序的 Illumina 的综合策略被获得,定序的 PacBio,和印射的 BioNano。作为到 lamiids 和 campanulids 的姐妹 taxon, E。ulmoides 经历了三倍由核心 eudicots 而是没有进一步整个染色体的复制分享了的一个古老的染色体 ? 在最后 1.25 亿年里。E。ulmoides 为涉及压力回答和第二等的代谢物的生合成的多重基因展出高表达式层次或基因数字扩大,它可以说明它的可观的环境适应性。与橡胶树(Hevea brasiliensis ) 相对照,它生产 cis 聚异式戊二我烯, E。ulmoides 演变综合经由 farnesyl diphosphate synthases (FPS ) 的长链的 trans 聚异式戊二我烯。而且, FPS 和橡胶延伸 factor/small 橡胶粒子蛋白质基因家庭从 H 独立地被扩展。brasiliensis 系。这些结果提供新卓见进 E. 的生物学 ? ulmoides 和聚异式戊二我烯生合成的起源。 | Ta-na Wuyun Lin Wang Huimin Liu Xuewen Wang Liangsheng Zhang Jeffrey L. Bennetzen Tiezhu Li Lirong Yang Panfeng Liu Lanying Du Lu Wang Mengzhen Huang Jun Qing Iili Zhu Wenquan Bao Hongguo Li Qingxin Du Jingle Zhu Hong Yang Shuguang Yang Hui Liu Hui Yue Jiang Hu Suoliang Yu Yu Tian Fan Liang Jingjing Hu Depeng Wang Ruiwen Gao Dejun Li Hongyan Du | 2018 | Molecular Plant2018，11，3： | 24 |
| 4 | Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus显示文摘 | Naru Zhang Rudragouda Channappanavar Cuiqing Ma Lili Wang Jian Tang Tania Garron Xinrong Tao Sumaiya Tasneem Lu Lu Chien-Te K Tseng Yusen Zhou Stanley Perlman Shibo Jiang Lanying Du | 2016 | Cellular & Molecular Immunology2016，13，2： | 12 |
| 5 | Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines显示文摘Seasonal influenza epidemics and influenza pandemics caused by influenza A virus(IAV)has resulted in millions of deaths in the world.The development of anti-IAV vaccines and therapeutics is urgently needed for prevention and treatment of IAV infection and for controlling future influenza pandemics.Hemagglutinin(HA)of IAV plays a critical role in viral binding,fusion and entry,and contains the major neutralizing epitopes.Therefore,HA is an attractive target for developing anti-IAV drugs and vaccines.Here we have reviewed the recent progress in study of conformational changes of HA during viral fusion process and development of HA-based antiviral therapeutics and vaccines. | Shibo Jiang Runming Li Lanying Du Shuwen Liu | 2010 | Protein & Cell2010，1，4： | 5 |
| 6 | A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2显示文摘Dear Editor,The pandemic of coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)highlights the need to develop effective and safe vaccines.Similar to SARS-CoV,SARS-CoV-2 recognizes angiotensin-converting enzyme 2(ACE2)as receptor for host cell entry.1,2 SARS-CoV-2 spike(S)protein consists of S1,including receptor-binding domain(RBD),and S2 subunits.3,4 We previously demonstrated that RBDs of SARS-CoV and MERS-CoV serve as important targets for the development of effective vaccines. | Wanbo Tai Xiujuan Zhang Aleksandra Drelich Juan Shi Jason CHsu Larry Luchsinger Christopher D.Hillyer Chien-Te KTseng Shibo Jiang Lanying Du | 2020 | Cell Research2020，30，10： | 5 |
| 7 | Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses显示文摘Dear Editor,The 2002–2003 global pandemic caused by severe acute respiratory syndrome coronavirus(SARS-CoV)infected around 8,000 people with 10%mortality(http://www.who.int/csr/sars/en/).The virus has a positivestranded RNA genome that encodes a large polyprotein(1a and 1ab),four structural proteins,including spike(S), | Lei-Ping Zeng Xing-Yi Ge Cheng Peng Wanbo Tai Shibo Jiang Lanying Du Zheng-Li Shi | 2017 | Science China(Life Sciences)2017，60，12： | 4 |
| 8 | Construction of the Chinese Veteran Clinical Research (CVCR) Platform for the assessment of non-communicable diseases显示文摘 | Tan Jiping Li Nan Gao Jing Guo Yuhe Hu Wei Yang Jinsheng Yu Baocheng Yu Jianmin Du Wei Zhang Wenjun Cui Lianqi Wang Qingsong Xia Xiangnan Li Jianjun Zhou Peiyi Zhang Baohe Liu Zhiying Zhang Shaogang Sun Lanying Liu Nan Deng Ruixiang Dai Wenguang Yi Fang Chen Wenjun Zhang Yongqing Xue Shenwu Cui Bo Zhao Yiming Wang Luning | 2014 | Chinese Medical Journal2014，，3： | 3 |
| 9 | Neutralizing antibodies for the prevention and treatment of COVID-19显示文摘Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)initiates the infection process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through the receptor-binding domain(RBD)in the S1 subunit of the viral spike(S)protein.This event is followed by virus–cell membrane fusion mediated by the S2 subunit,which allows virus entry into the host cell.Therefore,the SARS-CoV-2 S protein is a key therapeutic target,and prevention and treatment of coronavirus disease 2019(COVID-19)have focused on the development of neutralizing monoclonal antibodies(nAbs)that target this protein.In this review,we summarize the nAbs targeting SARS-CoV-2 proteins that have been developed to date,with a focus on the N-terminal domain and RBD of the S protein.We also describe the roles that binding affinity,neutralizing activity,and protection provided by these nAbs play in the prevention and treatment of COVID-19 and discuss the potential to improve nAb efficiency against multiple SARSCoV-2 variants.This review provides important information for the development of effective nAbs with broad-spectrum activity against current and future SARS-CoV-2 strains. | Lanying Du Yang Yang Xiujuan Zhang | 2021 | Cellular & Molecular Immunology2021，18，10： | 2 |
| 10 | Research anddevelopment of universal influenza vaccines显示文摘 | Lanying Du Yusen Zhou Shibo Jiang | 2010 | Mi-crobes and Infection2010，12，： | 1 |
| 11 | Isolation, identification and antioxidative capacity of water-soluble phenylpropanoid compounds from Rhodiola crenulata显示文摘 | Danjun Chen Junting Fan Peng Wang Lanying Zhu Yang Jin Yan Peng Shuhu Du | 2012 | Food Chemistry2012，，4： | 1 |
| 12 | Advances in the research and development of therapeutic antibodies against the Zika virus显示文摘The Zika virus(ZIKV)is an arbovirus in the same family,Flaviviridae,as the dengue virus(DENV),the West Nile virus,the yellow fever virus,and the Japanese encephalitis virus.ZIKV has been a recent research focus because of its close association with severe human diseases and syndromes,particularly congenital Zika syndrome,which includes fetal microcephaly and other brain abnormalities.1 The ZIKV envelope(E)protein is a major structural protein involved in receptor binding,viral entry,and fusion.It is arranged as a dimer,with each monomer consisting of three domains(DI,DII,and DIII),a stem region,and a transmembrane region.2 The ZIKV E protein induces the production of potent neutralizing antibodies against ZIKV and is thus a key target for the development of therapeutic ZIKV antibodies. | Shibo Jiang Lanying Du | 2019 | Cellular & Molecular Immunology2019，16，1： | 0 |
| 13 | SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies显示文摘A recent paper published in Science describes the detection of IgG antibody responses in individuals infected by severe acute respiratory syndrome coronavirus(SARS-CoV-2).The authors also examined the duration of antibody production and the correlation between IgG antibody titers and neutralizing antibody titers.1 This study provides information about the kinetics of antibody production,and the functionality and longevity of these antibodies,in patients with Coronavirus Disease 2019(COVID-19).The SARS-CoV-2 genome encodes spike(S),nucleocapsid,membrane,and envelope structural proteins.The S protein plays a key role in viral infection and pathogenesis. | Yang Yang Lanying Du | 2021 | Signal Transduction and Targeted Therapy2021，6，3： | 0 |
| 14 | Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants显示文摘Severe acute respiratory coronavirus 2(SARS-CoV-2),the causative agent of coronavirus disease 2019(COVID-19),has led to a pandemic with severe economic losses.The viral surface spike(S)protein comprises two subunits:S1 and S2.S1 contains an N-terminal domain(NTD)and a C-terminal domain(CTD)(i.e.,the receptor binding domain(RBD))[1,2].The RBD itself comprises core and receptor binding motif(RBM)regions(Fig.1a).During virus infection in humans,the RBD of S1 binds to the cellular receptor angiotensin-converting enzyme 2(ACE2)(Fig.1b),and S2 mediates viral entry and membrane fusion[1,3].Thus,the S protein is a critical vaccine and therapeutic target.The prefusion S protein exists as a trimer consisting of three RBDs;of these,the RBD in the“up”confirmation binds to ACE2(Fig.1c).SARS-CoV-2 has undergone frequent mutations since its emergence in 2019,and a number of mutated S protein residues have been identified,including in the RBD.Alpha(B.1.1.7),Beta(B.1.351),and Gamma(P.1)are previously circulating variants of concern(VOCs);in contrast,Delta(B.1.617.2),Omicron(B.1.1.529)BA.1,and other Omicron subvariants(BA.2,BA.3,BA.4,and BA.5),as well as BA.1/BA.2 circulating recombinant forms such as XE,are currently circulating VOC strains[4].Compared with the original SARS-CoV-2,the Omicron variant carries more mutations than any other variant identified thus far,among which approximately 39 and 15 substitutions are within the S protein and RBD,respectively,of the BA.1 subvariant. | Yang Yang Lanying Du | 2022 | Cellular & Molecular Immunology2022，19，8： | 0 |
| 15 | Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant显示文摘The newly emerged omicron strain of SARS-CoV-2 is spreading fast globally,replacing the previously dominant delta strain in many parts of the world[1].Compared to the early prototypic strains,the delta strain evades the human immune system more easily,causing many breakthrough infections in vaccinated people[2].It is imperative to understand in a timely fashion whether the omicron strain escapes immune surveillances.The information will be critical for public health measures. | Wei Zhang Linfen Huang Gang Ye Qibin Geng Nwando Ikeogu Morgan Harris Gayathri Dileepan Kristina Burrack Lanying Du Anne Frosch Fang Li | 2022 | Cellular & Molecular Immunology2022，19，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员